New indigenous antibody discovery platform to transform diagnostics in India

A team of researchers at the Indian Institute of Technology Roorkee IIT Roorkee have developed a nextgeneration antibody discovery platform that has the potential to transform diagnostics and therapeutics for diseasesThe research involves the development of an ultralarge highdiversity singledomain antibody nanobody libraryFrom infectious diseases cancer autoimmune disorders and emerging pathogens the platform enables rapid identification of highly stable and highaffinity antibodiesBy significantly reducing discovery timelines the innovation addresses a critical gap in healthcare response particularly during public health emergenciesldquoBy developing a universal highdiversity antibody discovery system within India we are strengthening national capabilities for faster disease response and accelerating the development of affordable diagnostics and therapeutics for populations that need them the mostrdquo said Prof Rajesh Kumar department of Biosciences and Bioengineering IIT RoorkeeThe research aligns with the vision of Atmanirbhar Bharat and Make in India and is especially relevant for low and middleincome countries where access to timely and costeffective healthcare solutions remains a persistent challengeThe initiative stresses the need to strengthen indigenous research capabilities generate intellectual property and reduce reliance on imported biologics It complements national efforts to promote translational research enhance pandemic preparedness and build longterm healthcare resilienceldquoThis development demonstrates how fundamental research combined with translational intent and industry collaboration can address pressing societal challengesrdquo said Prof K K Pant director IIT RoorkeeTo accelerate realworld deployment IIT Roorkee has also entered into a strategic industryndashacademia collaboration to support technology transfer scaleup and validation of antibodybased solutionsAs part of this effort the Institute said it has signed a Memorandum of Understanding MoU with IMGENEX India to promote collaborative research codevelopment of advanced biologics and capacity building in areas such as antibody engineering diagnostics therapeutics and bioprocess developmentThis story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever